Lantheus (LNTH) AI Stock Analysis

• Market Cap: $3.78B
• Dividend Yield: N/A
• Average Volume (3M): 2.15M
• Price to Earnings (P/E): 14.8
• Beta (1Y): 0.43
• Revenue Growth: 5.75%
• EPS Growth: -37.03%
• Country: US
• Employees: 808
• Sector: Healthcare
• Sector Strength: 47
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 1.57
• Shares Outstanding: 67,994,150
• 10 Day Avg. Volume: 2,355,630
• 30 Day Avg. Volume: 2,151,848
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 1.50
• Enterprise Value/Revenue: 3.73
• Enterprise Value/Gross Profit: 5.85
• Enterprise Value/Ebitda: 12.41
• 1Y Price Target: $83.00
• Price Target Upside: 46.02% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 10

• Rating: 58 Neutral
• Price Target: $58.00 ▲(2.04% Upside)

Lantheus faces significant challenges with a lowered financial outlook and bearish technical indicators, which weigh heavily on its stock score. Despite these challenges, strong financial performance and strategic initiatives offer potential for future improvement.

Positive Factors

Analyst Confidence

Analyst reiterates the Buy rating, expressing long-term confidence in the company's potential despite current challenges.

Portfolio Expansion

The acquisition of Life Molecular Imaging added the FDA-approved NEURACEQ to LNTH's portfolio, expanding its diagnostic and therapeutic capabilities.

Stock Buyback

The Board of Directors authorized the repurchase of up to $400M of LNTH's common stock, which can be seen as a vote of confidence in the company's future value.

Negative Factors

Competitive Pressures

Management highlighted intensified competitive pressures in the market, particularly affecting Pylarify revenues.

Market Share Loss

Management expects continued market share loss, coupled with net price decline, in both the third and fourth quarter.

Revenue Guidance Cut

The company lowered its guidance for the fiscal year, indicating significant cuts in both revenue and EPS projections.

Lantheus Business Overview & Revenue Model

Company Description

Lantheus Holdings, Inc. is a global leader in the development, manufacturing, and commercialization of innovative diagnostic imaging agents and therapies, primarily focused on oncology, cardiology, and neurology. The company specializes in radiopharmaceuticals and molecular imaging, offering products that aid in the detection and treatment of various diseases, including cancer. Its core products include Positron Emission Tomography (PET) imaging agents and other medical imaging solutions that enhance diagnostic accuracy and patient care.

How the Company Makes Money

Lantheus generates revenue primarily through the sale of its diagnostic imaging agents and related products. The company's revenue model is based on the commercialization of its proprietary radiopharmaceuticals, which are sold to hospitals, imaging centers, and other healthcare providers. Key revenue streams include direct sales of its imaging agents, such as Gallium-68 and other PET tracers, as well as collaboration agreements with pharmaceutical companies for the development and distribution of novel imaging agents. Additionally, Lantheus may benefit from strategic partnerships and collaborations, which can enhance its product offerings and expand its market reach, contributing to its overall earnings.

Lantheus Financial Statement Overview

Summary

Lantheus presents a solid financial position with strong profitability and cash flow metrics. While there are concerns regarding recent revenue growth and net profit margins, the company maintains strong operational efficiency and cash flow generation. Improved leverage management is noted, though monitoring of debt levels is advisable.

Income Statement

Lantheus has shown strong gross profit margins consistently above 60% in recent years, indicating efficient cost management. However, the TTM data shows a slight decline in revenue growth rate and net profit margin compared to previous years, which could be a concern if the trend continues. Despite this, the company maintains a healthy EBIT and EBITDA margin, reflecting robust operational efficiency.

Balance Sheet

The company's debt-to-equity ratio has improved over time, indicating better leverage management, though it remains moderately high. Return on equity has been strong, suggesting effective use of shareholder funds. The equity ratio is stable, showing a balanced approach to financing assets through equity.

Cash Flow

Lantheus has demonstrated impressive free cash flow growth, particularly in the TTM period, which is a positive indicator of financial health. The operating cash flow to net income ratio is strong, suggesting good cash generation relative to reported earnings. The free cash flow to net income ratio is also healthy, indicating efficient conversion of earnings into cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.52B	1.53B	1.30B	935.06M	425.21M	339.41M
Gross Profit	969.38M	988.29M	709.54M	581.70M	187.69M	138.76M
EBITDA	457.27M	515.27M	491.00M	81.83M	-25.00M	22.69M
Net Income	271.00M	312.44M	326.66M	28.07M	-71.28M	-13.47M
Balance Sheet
Total Assets	2.12B	1.98B	1.65B	1.32B	863.78M	869.82M
Cash, Cash Equivalents and Short-Term Investments	695.57M	912.81M	713.66M	415.65M	98.51M	79.61M
Total Debt	615.49M	619.44M	616.95M	558.07M	174.76M	218.40M
Total Liabilities	949.29M	892.33M	835.26M	874.11M	399.35M	355.62M
Stockholders Equity	1.17B	1.09B	815.89M	447.15M	464.44M	514.21M
Cash Flow
Free Cash Flow	473.19M	493.13M	258.70M	263.43M	41.78M	3.92M
Operating Cash Flow	527.46M	544.75M	305.26M	281.78M	53.92M	16.40M
Investing Cash Flow	-370.59M	-226.01M	5.94M	-276.55M	3.68M	-4.91M
Financing Cash Flow	-218.42M	-118.54M	-13.06M	311.69M	-39.33M	-21.86M

Lantheus Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 56.84
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LNTH, the sentiment is Negative. The current price of 56.84 is below the 20-day moving average (MA) of 58.77, below the 50-day MA of 70.15, and below the 200-day MA of 85.57, indicating a bearish trend. The MACD of -4.10 indicates Negative momentum. The RSI at 39.36 is Neutral, neither overbought nor oversold. The STOCH value of 48.02 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LNTH.

Lantheus Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NBIX	78 Outperform	$13.57B	40.39	13.39%	―	18.42%	1.47%
RDY	75 Outperform	$12.02B	18.08	17.48%	0.64%	13.13%	-0.47%
VTRS	59 Neutral	$12.14B	―	-19.77%	4.61%	-7.47%	-438.39%
LNTH	58 Neutral	$3.78B	14.78	24.71%	―	5.75%	-37.03%
TEVA	58 Neutral	$20.55B	―	-2.31%	―	2.43%	64.37%
Sector *	51 Neutral	$7.83B	-0.18	-40.10%	2.29%	21.46%	-2.03%
PRGO	51 Neutral	$3.26B	―	-1.32%	4.77%	-2.32%	35.46%

Lantheus Corporate Events

Lantheus CCO Amanda Morgan Takes Leave of Absence

Lantheus Holdings, Inc. announced that Amanda Morgan, the Chief Commercial Officer, will take a leave of absence from the company for personal reasons, effective August 8, 2025.

Lantheus Announces FDA Acceptance of New Drug Application

On August 6, 2025, Lantheus announced the FDA’s acceptance of a new drug application for a new formulation of its piflufolastat F-18 imaging agent, which could significantly increase patient access. The company also reported its second-quarter financial results, highlighting a revenue of $378 million and a strategic acquisition of Life Molecular Imaging, which expands its product portfolio and market reach. Additionally, Lantheus’ board authorized a $400 million stock repurchase program, reflecting confidence in its long-term growth strategy.

Lantheus Completes Acquisition of Life Molecular Imaging

On July 21, 2025, Lantheus completed its acquisition of Life Molecular Imaging Limited, enhancing its capabilities in Alzheimer’s disease diagnostics with the addition of Neuraceq, an F-18 PET imaging agent. The acquisition, valued at $350 million, strengthens Lantheus’s international presence and R&D capabilities. Additionally, Dr. Ludger Dinkelborg, former CEO of Life Molecular Imaging, was appointed as Lantheus’s Head of Research and Development, effective August 1, 2025, to lead various strategic areas, including Clinical Development and AI/Biomarkers Solutions.